Analysis of toxic effects and efficacy of tyrosine kinase inhibitors as first line treatment in renal cell canrcinoma.
Not Applicable
- Conditions
- Health Condition 1: null- Newly diagnosed patients of metastatic Renal Cell Carcinoma
- Registration Number
- CTRI/2015/05/005792
- Lead Sponsor
- ot Applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Inclusion criteria :
1. Age more than 18 years.
2. Performance status ECOG 0 to 2.
3. Metastatic RCC with measurable disease.
4. All histopathological diagnosis of renal cell carcinoma.
5. Treated with TKIs (Sorafenib, Sunitinib & Pazopanib) in 1st line setting.
Exclusion Criteria
1. Non metastatic RCC.
2. Non measurable disease.
3. Patients progressed on first line treatment.
4. Uncontrolled co morbidities.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PRIMARY OUTCOME: <br/ ><br>1. To determine PFS (Progression free survival) with first line treatment with Tyrosine Kinase inhibitors (Sunitinib, Sorafenib, Pazopanib) in newly diagnosed patients of metastatic RCC <br/ ><br>2.To determine toxicity with these drugs in this group of patients <br/ ><br>Timepoint: 1. At the end of the study <br/ ><br>2. at each follow up visit
- Secondary Outcome Measures
Name Time Method Secondary objectives: <br/ ><br>1.To determine OS (Overall survival) with first line treatment with Tyrosine Kinase inhibitors (Sunitinib, Sorafenib, Pazopanib) in newly diagnosed patients of metastatic RCC <br/ ><br>Timepoint: At the end of study